Skye Bioscience, Inc. (SKYE) Stock Ticker
SKYE right now
Market factors today
Unlock the full SKYE picture
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
SKYE stock facts
| Ticker symbol | SKYE |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $7.3M |
| CEO | Punit Dhillon |
| Employees | 2 |
| Headquarters | San Diego, CA, US |
| IPO date | 2015-01-06 |
| Website | skyebioscience.com |
What you can see for SKYE on Tickr
Live SKYE price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SKYE report.
Rankings
FAQ
What is the ticker symbol for Skye Bioscience, Inc.?
The ticker symbol for Skye Bioscience, Inc. is SKYE, listed on the NASDAQ.
What is SKYE?
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company…